Evidence map›Paper›PMID 40121554›Full record

ArticleBriefings in bioinformatics2025

BAMBI integrates biostatistical and artificial intelligence methods to improve RNA biomarker discovery.

Peng Zhou, Zixiu Li, Feifan Liu, Euijin Kwon, Tien-Chan Hsieh, Shangyuan Ye, Shobha Vasudevan, Jung Ae Lee, Khanh-Van Tran, Chan Zhou

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peng ZhouDepartment of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Zixiu LiDepartment of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Feifan LiuDepartment of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Euijin KwonDepartment of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Tien-Chan HsiehDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Shangyuan YeBiostatistics Shared Resource, Knight Cancer Institute, Oregon Health and Science University, 2720 S Moody Ave, Portland, OR 97201, United States.
Shobha VasudevanBrown RNA Center, Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02903, United States.
Jung Ae LeeDepartment of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Khanh-Van TranDivision of Cardiology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Chan ZhouDepartment of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.ORCID 0000-0002-0351-6235

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA biomarkers enable early and precise disease diagnosis, monitoring, and prognosis, facilitating personalized medicine and targeted therapeutic strategies. However, identification of RNA biomarkers is hindered by the challenge of analyzing relatively small yet high-dimensional transcriptomics datasets, typically comprising fewer than 1000 biospecimens but encompassing hundreds of thousands of RNAs, especially noncoding RNAs. This complexity leads to several limitations in existing methods, such as poor reproducibility on independent datasets, inability to directly process omics data, and difficulty in identifying noncoding RNAs as biomarkers. Additionally, these methods often yield results that lack biological interpretation and clinical utility. To overcome these challenges, we present BAMBI (Biostatistical and Artificial-intelligence Methods for Biomarker Identification), a computational tool integrating biostatistical approaches and machine-learning algorithms. By initially reducing high dimensionality through biologically informed statistical methods followed by machine learning-based feature selection, BAMBI significantly enhances the accuracy and clinical utility of identified RNA biomarkers and also includes noncoding RNA biomarkers that existing methods may overlook. BAMBI outperformed existing methods on both real and simulated datasets by identifying individual and panel biomarkers with fewer RNAs while still ensuring superior prediction accuracy. BAMBI was benchmarked on multiple transcriptomics datasets across diseases, including breast cancer, psoriasis, and leukemia. The prognostic biomarkers for acute myeloid leukemia discovered by BAMBI showed significant correlations with patient survival rates in an independent cohort, highlighting its potential for enhancing clinical outcomes. The software is available on GitHub (https://github.com/CZhouLab/BAMBI).

Indexed as

Artificial IntelligenceBiomarkers, TumorBiostatisticsComputational BiologyRNASoftwareAlgorithmsBiomarkersHumansMachine LearningBiomarkersBiomarkers, TumorRNAbiomarkerdiagnosis and prognosishigh-dimensionality reductionmachine learningnoncoding RNAstatistics

Identifiers

PMID40121554
PMCPMC11929966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.